Zhilong Yuan

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld et al. · Journal of Clinical Oncology · 2007 · 644 citations · Full text

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 231 citations

Hematological Malignancy, Surgical Oncology, Medicine +6

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

Joseph A. Sparano, Semiglazov Vf, Sergei Tjulandin et al. · Journal of Clinical Oncology · 2009 · 116 citations · Full text

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

Josep Tabernero, Luc Dirix, Patrick Schöffski et al. · Clinical Cancer Research · 2011 · 62 citations · Full text

Isotonic designs for phase I cancer clinical trials with multiple risk groups

Zhilong Yuan, Rick Chappellb · Clinical Trials · 2004 · 58 citations